- Home
- ACVA vs WGS Comparison
ACVA vs WGS Comparison
Compare ACVA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- WGS
- Stock Information
- Founded
- ACVA 2014
- WGS 2017
- Country
- ACVA United States
- WGS United States
- Employees
- ACVA N/A
- WGS N/A
- Industry
- ACVA Business Services
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- ACVA Consumer Discretionary
- WGS Technology
- Exchange
- ACVA Nasdaq
- WGS Nasdaq
- Market Cap
- ACVA 2.7B
- WGS 2.4B
- IPO Year
- ACVA 2021
- WGS N/A
- Fundamental
- Price
- ACVA $13.75
- WGS $102.86
- Analyst Decision
- ACVA Strong Buy
- WGS Strong Buy
- Analyst Count
- ACVA 11
- WGS 8
- Target Price
- ACVA $22.27
- WGS $91.25
- AVG Volume (30 Days)
- ACVA 1.6M
- WGS 961.4K
- Earning Date
- ACVA 08-11-2025
- WGS 07-29-2025
- Dividend Yield
- ACVA N/A
- WGS N/A
- EPS Growth
- ACVA N/A
- WGS N/A
- EPS
- ACVA N/A
- WGS 0.05
- Revenue
- ACVA $674,164,000.00
- WGS $362,321,000.00
- Revenue This Year
- ACVA $24.03
- WGS $22.16
- Revenue Next Year
- ACVA $21.95
- WGS $19.63
- P/E Ratio
- ACVA N/A
- WGS $2,068.79
- Revenue Growth
- ACVA 32.89
- WGS 48.70
- 52 Week Low
- ACVA $11.88
- WGS $25.32
- 52 Week High
- ACVA $23.46
- WGS $117.75
- Technical
- Relative Strength Index (RSI)
- ACVA 32.21
- WGS 69.66
- Support Level
- ACVA $13.98
- WGS $78.99
- Resistance Level
- ACVA $15.32
- WGS $107.31
- Average True Range (ATR)
- ACVA 0.50
- WGS 5.57
- MACD
- ACVA -0.14
- WGS 1.87
- Stochastic Oscillator
- ACVA 9.68
- WGS 82.86
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.